Athanor Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Athanor Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-32,153	Closed	-$68K	–	1084
2020 Q4	$68K	Buy	+32,153	New	+$53K	﹤0.01%	688
2019 Q4	–	Sell	-13,219	Closed	-$14K	–	404
2019 Q3	$14K	Sell	13,219 -85,181	-87%	-$116K	﹤0.01%	204
2019 Q2	$177K	Buy	+98,400	New	+$158K	0.02%	134

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

GPC

Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Athanor Capital's INFI Position: Q1 2021 in Review

Athanor Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2021, closing a stake of 32,153 shares — an estimated $68K sold.

Athanor Capital first reported a position in INFI in Q2 2019 and held it in 3 quarters. The position peaked at $177K in Q2 2019. 83 funds tracked by Wall St. Rank hold INFI as of Q1 2021.

Athanor Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 32,153 Infinity Pharmaceuticals, Inc. shares in Q1 2021, an estimated $68K.
Athanor Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
Athanor Capital's Infinity Pharmaceuticals, Inc. position peaked at $177K in Q2 2019.
83 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.